7 news items
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema
IONS
31 May 24
Donidalorsen delivered significant and sustained
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
BIIB
IONS
16 May 24
placebo-controlled treatment period, with sustained reductions in ATXN2 but no impact on NfL or clinical outcome measures over 40+ weeks of follow-up
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB
IONS
16 May 24
similar to those seen during the 6-month placebo-controlled treatment period, with sustained reductions in ATXN2 but no impact on NfL or clinical outcome
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
BIIB
IONS
16 May 24
similar to those seen during the 6-month placebo-controlled treatment period, with sustained reductions in ATXN2 but no impact on NfL or clinical
Ionis Publishes 2023 Corporate Responsibility Report
IONS
25 Apr 24
a steady cadence of new medicines to people with serious diseases and believe our long-standing commitment to operating responsibly and sustainably
orba3pgetfuk71w83p59zed6w0vlz51w2kc c4i
IONS
7 Apr 24
FCS at six months. In addition, olezarsen demonstrated robust and sustained reductions in TGs and serum apolipoprotein C-III (apoC-III) levels
ecge3ithbi47hxr l6fs6gbxweirpexuh8w0srjvd0vehhmhbk8zc
BIIB
IONS
6 Mar 24
reside, to deliver treatment where the disease starts.3 SPINRAZA has demonstrated sustained efficacy across ages and SMA types
- Prev
- 1
- Next